Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

This Combined Synopsis/Solicitation opportunity from Department Of Health And Human Services was posted on April 11, 2024. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Scientific Data Services

Closed
75N99224Q00002Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

General Info

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Place of Performance

Bethesda, MD, 20892, USA

Set-Aside

NONE

Documents

7

Applicable Provisions and Clauses - ARPA-H

PDF, High priority: read this firstspecifications
High

ARPA-H HEROES Program Outcome Toolkit Statement of Need (Amend 0001)

PDF, High priority: read this firstsow
High

Continuation Sheet 75N99224Q0002

PDF, High priority: read this firstrfq
High

HEROES Toolkit Data Format Requirements

PDF, High priority: read this firstspecifications
High

Solicitation 75N99224Q00002 Amendment 0001

PDF, High priority: read this firstamendment
High

Solicitation 75N99224Q00002 - NIH ARPA-H

PDF, High priority: read this firstrfp
High

RFQ 75N99224Q00002 Q&A Responses

PDF, Low priorityq-and-a
Low

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

2 updates
PhaseClosed
Posted

Combined Synopsis

Notice updated

The notice description changed.

Notice updated

The notice description changed.

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → Advanced Research Projects Agency For Health (arpa-H)
Contacts2 people available
OfficeWashington, DC, 20005, USA
Office AddressWashington, DC, 20005, USA
Contacts

Full Description

Show more
04/11/24: The purpose of Amendment 0001 is to update the Solicitation and Statement of Need with red font changes, and attach the RFQ Q&A. No other changes were made. ---------------------------------------------- Combined Synopsis/Solicitation Solicitation Number: 75N99224Q00002 Purchase Description: HEROES Data Variables This is a Combined Synopsis/Solicitation Notice for commercial items prepared in accordance with the format in FAR 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation/notice; responses/quotes are being requested, further written solicitation will not be issued. This solicitation will be posted to the sam.gov as a Full and Open Competition. The ARPA-H is issuing this combined synopsis/solicitation, 75N99224Q00002, as a Request for Quote using FAR Part 12 Acquisition of Commercial Item, FAR Part 13 Simplified Acquisition Procedures, and Subpart 13.5 Simplified Procedures for Certain Commercial Products and Commercial Services. This is not a small business set-aside; the North American Industrial Classification System (NAICS) code for this procurement is 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology), and size standard of 1,000 employees. The Government intends to award a Firm Fixed-Price Commercial Award. The solicitation document and incorporated provisions and clauses are in effect through Federal Acquisition Circular 2024-03 effective February 23, 2024, and Health and Human Services Acquisition Regulation Supplement (HHSAR) via 48 C.F.R. Ch. 3 effective October 1, 2023, respectively. All federal and state laws and regulations are in effect during the term of the contract. DESCRIPTION OF ITEMS/SERVICE: All CLINs F.O.B. Destination. To effectively support the HEROES program's data toolkit, ARPA-H outlines minimal requirements that encompass a comprehensive data variable framework and meticulous data management strategies. For Severe Obstetric Complications (SOC), the requirements align with definitions by CMS, including a broad spectrum of conditions ranging from acute myocardial infarction to ventilation. Additionally, the HEROES program specifies data variables for admissions related to mental health conditions and leaves room for the inclusion of further variables over the term agreement. These datasets should be linked to a de-identified unique patient ID and extend to capture claims or health system encounters 60 days postpartum, diverging from current specifications. The contractor shall provide all items IAW Attachment 3 - Statement of Need. CLIN STRUCTURE: The contractor shall complete Attachment 2 and include shipping cost in the cost line-item cost. CLIN 1001: Severe Obstetric Complications Data Variables Product/Service Code: B529 Product/Service Description: SPECIAL STUDIES/ANALYSIS- SCIENTIFIC DATA Period of Performance: 08/30/2024 to 08/29/2025 Quantity: 12 Unit of Issue: Month Unit Price: $_____________ Extended Price (Quantity X Unit Price): $________________ CLIN 1002: Atherosclerotic Cardiovascular Disease and Associated 10-Year Risk Scores Data Variable Product/Service Code: B529 Product/Service Description: SPECIAL STUDIES/ANALYSIS- SCIENTIFIC DATA Period of Performance: 08/30/2024 to 08/29/2025 Quantity: 12 Unit of Issue: Month Unit Price: $_____________ Extended Price (Quantity X Unit Price): $________________ CLIN 1003: Additional Data Variables specific to HEROES program Product/Service Code: B529 Product/Service Description: SPECIAL STUDIES/ANALYSIS- SCIENTIFIC DATA Period of Performance: 08/30/2024 to 08/29/2025 Quantity: 12 Unit of Issue: Month Unit Price: $_____________ Extended Price (Quantity X Unit Price): $________________ CLIN 2001: Severe Obstetric Complications Data Variables Product/Service Code: B529 Product/Service Description: SPECIAL STUDIES/ANALYSIS- SCIENTIFIC DATA Period of Performance: 08/30/2025 to 08/29/2026 Quantity: 12 Unit of Issue: Month Unit Price: $_____________ Extended Price (Quantity X Unit Price): $________________ CLIN 2002: Atherosclerotic Cardiovascular Disease and Associated 10-Year Risk Scores Data Variable Product/Service Code: B529 Product/Service Description: SPECIAL STUDIES/ANALYSIS- SCIENTIFIC DATA Period of Performance: 08/30/2025 to 08/29/2026 Quantity: 12 Unit of Issue: Month Unit Price: $_____________ Extended Price (Quantity X Unit Price): $________________ CLIN 2003: Additional Data Variables specific to HEROES program Product/Service Code: B529 Product/Service Description: SPECIAL STUDIES/ANALYSIS- SCIENTIFIC DATA Period of Performance: 08/30/2025 to 08/29/2026 Quantity: 12 Unit of Issue: Month Unit Price: $_____________ Extended Price (Quantity X Unit Price): $________________ PLACE OF DELIVERY: Bethesda, MD 20892 DELIVERY DATE(S): Monthly after effective date of the contract. LIST OF ATTACHMENTS: Attachment 1 - Solicitation SF33 Attachment 2 - Continuation Sheet (CLINs) Attachment 3 - Statement of Need Attachment 4 - Applicable Provisions and Clauses Attachment 5 - HEROES Toolkit Data Format Requirements Attachment 6 - RFQ Q&A_Responses_Final QUESTIONS: Questions shall be received no later than Tuesday 09 April 2024 at 4:00 pm (Eastern Daylight Time). Forward responses by e-mail to contact@example.gov and contact@example.gov. Inquiries received after the deadline will not be responded to. QUOTES: Follow ALL directions and requirements within the solicitation. Incomplete submittals may be considered nonresponsive for failure to provide a complete submittal. Quotes in response to this RFQ will be valid for 120 days (unless a different period is proposed by the Vendor). Responses/quotes MUST be received no later than Friday 19 April 2024 at 12:00 am (Eastern Daylight Time). Forward responses by e-mail to contact@example.gov. Any quote, modification, or revision of a quote received after the exact time specified in this solicitation shall be determined as late and will not be considered. If a late quote is received before award is made, only the Contracting Officer could make the determination that accepting the late quote would not unduly delay the acquisition, and it was the only quote received. **Only the three lowest quotes deemed technically acceptable will be considered for evaluation for award.** OTHER INFORMATION: Per FAR Subpart 4.1102, offerors are required to be registered in System for Award Management (SAM) at time of submission of quote and the potential awardee must be determined responsible pursuant to FAR 9.104 to be eligible for award. Failure to be actively registered in SAM at the time of submission and be deemed responsible will result in the offer being ineligible for award. Conflict of Interest: If the offeror currently provides support or anticipates providing support to other vendors which may create or represent an actual or potential Organizational Conflict of Interest (OCI), the offeror shall immediately disclose the actual or potential OCI to ARPA-H in accordance with FAR Subpart 9.5. Disclosure may be made via memo on offeror company letterhead and included after the cover letter in the quote for each area impacted. The offeror agrees to disclose information concerning the actual or potential conflict with any quote relating to any work in the contract for the duration of the contract term. All actual or potential OCI situations shall be handled by the Contracting Officer (CO) in accordance with FAR Subpart 9.5. To avoid any potential conflicts of interest, by providing a quote the offeror agrees that it may not restrict the conception, design, or configuration of its analyses, recommendations or findings in connection with this RFQ and any subsequent contract in a manner that will favor any endeavors that are its separate marketing efforts or those of its affiliates, subordinates, or other commercial ventures. Notice to Offeror. The Government reserves the right to cancel this Request for Quote (RFQ), either before or after suspense date. In the event the Government cancels this RFQ, the Government has no obligation to reimburse an offeror for any costs. The contractor shall not request, nor will the Government make, payment for any preliminary measurement, quotes, bids, site visit, time or quotation cost incurred. Interchanges. The Government intends to award a purchase order without interchanges with respective vendors/quoters. The Government, however, reserves the right to conduct interchanges if deemed in its best interest. Under appropriate circumstances, interchanges can be an effective method to improve the Government's evaluation of Offerors' quoted approaches and may reduce acquisition cycle time. Interchanges may be written, email, phone call, etc., or any method which would accurately capture the contemporaneous sharing of information between the Government and the Offerors. Interchanges may also be oral conversations between the Government and the Offerors. Site Visit: A site visit will not be held for this requirement. INSTRUCTIONS TO OFFERORS: Offerors shall comply with FAR 52.212-1 Instructions to Offerors - Commercial Products and Commercial Services (Sep 2023) FAR 52.212-1 is hereby tailored as follows: 1. Any inconsistency between FAR Provision 52.212-1 and the Addendum to FAR 52.212-1 shall be solved by giving precedence to the Addendum to FAR 52.212-1. 2. After receipt of quotes the Government may, with or without notice, negotiate with and, if desired, seek quote revisions from as many or as few quoters as it, in its discretion, deems appropriate. 3. The term - offeror or - offer as used in FAR 52.212-1 shall be understood to mean - quoter and - quote, respectively. Further, the term - award shall be understood to describe the Government's issuance of an order or contract. 4. The Government will consider all quotes that are timely received and will not consider late quotes. Failure of a quote to address any items required in the submission package may make a quote unacceptable and ineligible for award. 5. Paragraph (b) of FAR Provision 52.212-1, Submission of Offers, is amended as follows: 5.1 In addition to the quote submission requirements stated in FAR provision 52.212-1, quoters shall provide the following, as part of the quote submission package, no later than the required time and date for quote submission: 5.1.1 SF33 complete and signed (Attachment 1) 5.1.1.1 Fill in the following blocks: 1, 12, 13, 14 if applicable, 15A/B/C if application, 16, 17, 18 5.1.2 Cover page to include the offeror's: 5.1.2.1 Company Name and Company Doing Business As (if applicable) 5.1.2.2 Physical Address 5.1.2.3 Cage code and Unique Entity ID 5.1.2.4 Point of Contact 5.1.2.5 Phone number 5.1.2.6 Email address 5.1.2.7 Business Type 5.1.2.7.1 Socio-economic category, if any, as it relates to the NAICS under Purchase description 5.1.2.8 Initial delivery date after award 5.1.2.9 Statement of Understanding of the Performance Work Statement 5.1.3 Firm Fixed Pricing to align with Continuation Sheet CLINs (complete Attachment 2 or equivalent with below information): 5.1.3.1 Price Per Unit 5.1.3.2 Price Per CLIN 5.1.3.3 Total Price 5.1.3.4 Discount Terms (if applicable) 5.1.3.5 Quote Number (if applicable) 5.1.4 Technical Capability 5.1.4.1 Quote must identify the data variable(s) covered under each line item. 5.1.4.2 Quote must include data variable description that reflects the characteristics identified in the statement of need to show that the quality will satisfy the Government's need. 5.1.4.3 Limit 20 pages for this section. Any quote attachments/exhibits/addendums, etc. count towards the page limitations. (End of Provision) EVALUATION: ADDENDUM TO FAR 52-212-2 EVALUATION'COMMERCIAL ITEMS (Nov 2021) Paragraph (a) is hereby replaced with the following: The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. Quotes that do not include all requested information in FAR 52.212-1 in 5.1.1 will be considered nonresponsive. Award will be made to the responsible offeror with the lowest price technically acceptable (LPTA) offer. The following factor(s) shall be used to evaluate offers: 1. Technical Capability: Items meet the Government requirement/specifications in the statement of need. Quotes that simply rephrase or restate the Government requirements without convincing rationale to address how the quoter intends to meet the requirement will be deemed unacceptable. If all requested information is not provided or does not meet the requirements identified, the Government will determine the quote to be nonresponsive and no longer considered for award. Information that is contained in pages exceeding the page limit will not be considered. 2. Price: 2.1 The lowest priced quote will be evaluated for technical acceptability first. The Government will evaluate quotes for acceptability but will not rank the quotes by non-price factors. If the Government receives fewer than three (3) quotes, all quotes will be evaluated for Technical Acceptability. If the Government receives more than three (3) quotes, the Government will only select the three (3) lowest priced quotes to evaluate for Technical Acceptability. The Government reserves the right to evaluate additional quotes for technical acceptability if it is in the Government's best interest to do so. The FAR 52.217-8 extension period shall be evaluated at an amount of 5/12th of the last yearly total evaluated price (i.e., equal to five months of performance). 2.2 Price will be evaluated using the total evaluated price (TEP) on the bottom-line price for the entire effort. A price is reasonable if, in its nature and amount, it does not exceed that which would be incurred by a prudent person in the conduct of competitive business. The Government may use various price analysis techniques and procedures to ensure a fair and reasonable price. Some of those techniques are, but not limited to, comparison of quoted prices received in response to the solicitation and/or comparison of quoted prices with the Independent Government Estimate. Prices must be determined fair and reasonable. 2.3 No additional information from the quoter will be required if the price is based on adequate price competition. In the event adequate price competition does not exist, the Contracting Officer will obtain information from the quoter to the extent required to determine the reasonableness of the offered prices. (End of Provision)

More opportunities from Department Of Health And Human Services → Advanced Research Projects Agency For Health (arpa-H)

Same awarding agency

NAICS: 541714
New
Federal
ARPA-H Emerging Health Innovators (EHI) Initiative
Solicitation # ARPA-H-SOL-26-150
The Advanced Research Projects Agency for Health (ARPA-H) Emerging Health Innovators (EHI) initiative, solicitation ARPA-H-SOL-26-150, seeks to identify and engage early-career investigators to develop cutting-edge biomedical, health, and community-engaged research. This opportunity is open to researchers from academic, nonprofit, and industry organizations, provided the Principal Investigator is within eight years of completing their first terminal degree. The initiative covers 16 specific topic areas, including AI in life sciences, brain stimulation, and human tissue platforms. Awards are issued as Other Transaction (OT) agreements, which are not subject to the Federal Acquisition Regulation (FAR). The selection process is a two-step submission involving an initial anonymized Solution Summary and a subsequent Full Proposal for selected candidates. Successful awards have a total value not to exceed 1,050,000 dollars over a three-year period, consisting of a 24-month base period capped at 700,000 dollars and an optional 12-month Director's Award period capped at 350,000 dollars. Payments are structured as fixed payments triggered by the completion of 12 discrete, measurable milestones. Full proposals are evaluated based on technical merit, innovativeness, feasibility, alignment with the ARPA-H mission to accelerate health outcomes, and price reasonableness. Administrative requirements include mandatory registration in SAM.gov and the use of the ARPA-H Solutions site for all submissions. Proposers must adhere to strict formatting templates for technical and management proposals, milestone schedules, and national policy requirements, including disclosures regarding organizational conflicts of interest and research security. Performance is monitored through a formal inspection and acceptance process where the government reviews deliverables within 14 calendar days. The tentative award start date is June 30, 2027, with full proposals due by February 10, 2027.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

7 days ago

DEADLINE

in 3 months
View Details
NAICS: 541715
Federal
Fast Assessment of Solutions, Therapeutics, Pharmaceuticals, and SupplieS (FASTPASS) Innovative Solutions Opening
Solicitation # ARPA-H-SOL-26-160
The Fast Assessment of Solutions, Therapeutics, Pharmaceuticals, and Supplies (FASTPASS) program, under solicitation ARPA-H-SOL-26-160, is an initiative by the Advanced Research Projects Agency for Health (ARPA-H) to develop a near real-time, non-destructive, AI-enabled screening system. The goal is to identify contamination, adulteration, and quality defects in pharmaceutical products through their packaging at ports of entry and other supply-chain nodes using multi-modal sensing and data fusion. This 54-month program is structured into three 18-month phases, culminating in a fieldable platform with validated training materials and integrated documentation capabilities. This procurement is conducted as a multiple-award Other Transaction (OT) Agreement rather than a standard federal contract, meaning it is governed by specific OT articles instead of the Federal Acquisition Regulation. Awards are based on the most advantageous proposals, with primary evaluation factors including innovation, soundness, execution planning, risk management, and team expertise. Payments are fixed and triggered by the successful completion of milestones, managed through the Payment Management System. Proposers must be registered in SAM.gov and provide detailed technical and cost proposals, including a milestone payment schedule and research security disclosures. Amendment 01 specifically updated the cost proposal narrative model and workbook to correct typographical errors and rename appendices.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

8 days ago

DEADLINE

in 13 days
View Details
NAICS: 541714
Federal
Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS)
Solicitation # ARPA-H-SOL-26-164
The Advanced Research Projects Agency for Health (ARPA-H) is soliciting proposals for the Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program under solicitation ARPA-H-SOL-26-164. This five-year initiative aims to create a reusable blueprint for future adaptive seamless platform trials through the integration of three technical areas: a Phaseless Design Engine, Continuous Inference, and Agentic Operations. The program is divided into two stages, with Stage I focusing on capability buildout, FDA engagement, and the onboarding of at least three intervention arms over 24 months, followed by a 36-month Stage II dedicated to validation and deployment. A critical go/no-go milestone is obtaining FDA authorization for the platform Master Protocol IND and at least one investigational arm by the end of Stage I. The government intends to make multiple awards via Other Transaction Agreements to proposers offering the most advantageous solutions based on innovation, feasibility, and technical merit at reasonable prices. Eligible entities must possess a Unique Entity Identifier and active SAM registration. Proposals are submitted in a phased approach, beginning with a Solution Summary and potentially progressing to a Solution Pitch package. Performance will be measured by the successful integration of the three technical areas and the achievement of specific program metrics. All work must adhere to ICH E6(R3) Good Clinical Practice and strict regulatory standards to ensure inspection readiness and participant safety.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

29 days ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
Federal
UNifying Imaging with QUantum Entanglement (UNIQUE) Innovative Solutions Opening (ISO)
Solicitation # ARPA-H-SOL-26-162
The Advanced Research Projects Agency for Health (ARPA-H) is seeking innovative solutions through the UNifying Imaging with QUantum Entanglement (UNIQUE) program, solicitation number ARPA-H-SOL-26-162. This 18-month, two-phase initiative aims to develop a new biomedical imaging paradigm by integrating anatomical, functional, and molecular data using quantum-derived observables and entangled 511 keV photon pairs. The scope is divided into two technical areas: the Imaging Core, which focuses on physical systems for generating and measuring quantum observables, and the Computational Foundation, which focuses on AI-driven reconstruction and multimodal data fusion. ARPA-H anticipates awarding multiple Other Transaction Agreements to eligible universities, non-profit organizations, and businesses. The submission process is two-staged, requiring Solution Summaries by late October 2026 and Full Proposals by December 15, 2026. Full proposals must consist of three volumes covering technical and management plans, cost proposals, and administrative requirements. Evaluation is based on technical innovation and feasibility, proposer expertise, potential to transform biomedicine, and cost reasonableness. Notably, for-profit organizations that are not small businesses under NAICS 541714 are required to provide a meaningful cost share. All participants must adhere to strict HHS regulations regarding human stem cell research and prohibitions on dangerous gain-of-function research and funding for foreign entities in countries of concern.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

about 1 month ago

DEADLINE

in about 2 months
View Details

Earlier notices in this NAICS code

Posted before this notice, open and closed

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS